LEVAQUIN Drug Patent Profile

When do Levaquin patents expire, and what generic alternatives are available?

Levaquin is a drug marketed by Janssen Pharms and is included in three NDAs.

The generic ingredient in LEVAQUIN is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levaquin

A generic version of LEVAQUIN was approved as levofloxacin by RISING on December 20^th, 2010.

Summary for LEVAQUIN

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	24
Patent Applications:	800
Drug Prices:	Drug price information for LEVAQUIN
What excipients (inactive ingredients) are in LEVAQUIN?	LEVAQUIN excipients list
DailyMed Link:	LEVAQUIN at DailyMed

See drug prices for LEVAQUIN

See drug sales revenues for LEVAQUIN

Recent Clinical Trials for LEVAQUIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Indonesia University	Phase 1/Phase 2
Novartis Pharmaceuticals	Phase 2
Harvard Medical School (HMS and HSDM)	Phase 2

See all LEVAQUIN clinical trials

Paragraph IV (Patent) Challenges for LEVAQUIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEVAQUIN	Oral Solution	levofloxacin	25 mg/mL	021721	1	2009-07-30

US Patents and Regulatory Information for LEVAQUIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	LEVAQUIN	levofloxacin	INJECTABLE;INJECTION	020635-001	Dec 20, 1996		DISCN	Yes	No
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-002	Dec 20, 1996		DISCN	Yes	No
Janssen Pharms	LEVAQUIN	levofloxacin	TABLET;ORAL	020634-001	Dec 20, 1996		DISCN	Yes	No
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-003	Dec 20, 1996		DISCN	Yes	No
Janssen Pharms	LEVAQUIN	levofloxacin	INJECTABLE;INJECTION	020635-004	Dec 20, 1996		DISCN	Yes	No
Janssen Pharms	LEVAQUIN	levofloxacin	SOLUTION;ORAL	021721-001	Oct 21, 2004		DISCN	Yes	No

Expired US Patents for LEVAQUIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	LEVAQUIN	levofloxacin	INJECTABLE;INJECTION	020635-001	Dec 20, 1996	4,382,892
Janssen Pharms	LEVAQUIN	levofloxacin	TABLET;ORAL	020634-003	Sep 8, 2000	5,053,407*PED
Janssen Pharms	LEVAQUIN	levofloxacin	TABLET;ORAL	020634-001	Dec 20, 1996	4,382,892
Janssen Pharms	LEVAQUIN	levofloxacin	TABLET;ORAL	020634-002	Dec 20, 1996	5,053,407*PED
Janssen Pharms	LEVAQUIN	levofloxacin	TABLET;ORAL	020634-002	Dec 20, 1996	4,382,892
Janssen Pharms	LEVAQUIN	levofloxacin	INJECTABLE;INJECTION	020635-001	Dec 20, 1996	5,053,407*PED

EU/EMA Drug Approvals for LEVAQUIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A	Quinsair	levofloxacin	EMEA/H/C/002789Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2015-03-25

International Patents for LEVAQUIN

See the table below for patents covering LEVAQUIN around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	19875012
Israel	63613	DIHYDROHALO OXO-PYRIDO(1,2,3-DE)(1,4)BENZOXAZINE CARBOXYLIC ACID DERIVATIVES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Yugoslavia	45524
Spain	8801251
Yugoslavia	186788
Canada	2440412

Supplementary Protection Certificates for LEVAQUIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0206283	SPC/GB97/085	United Kingdom		PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
0206283	C980016	Netherlands		PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
0206283	98C0041	Belgium		PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606

LEVAQUIN (Levofloxacin) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Levofloxacin, marketed as LEVAQUIN by Johnson & Johnson, is a broad-spectrum fluoroquinolone antibiotic. Its market performance has been shaped by patent expirations, generic competition, and evolving clinical guidelines. This analysis examines LEVAQUIN's historical market penetration, patent landscape, and projected financial trajectory.

What is Levofloxacin's Therapeutic Class and Mechanism of Action?

Levofloxacin is a synthetic chemotherapeutic antibacterial agent. It is the L-isomer of ofloxacin. Levofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. This mechanism leads to rapid bacterial cell death.

Levofloxacin is indicated for the treatment of various bacterial infections, including:

• Pneumonia (community-acquired, hospital-acquired)
• Acute bacterial sinusitis
• Acute bacterial exacerbations of chronic bronchitis
• Urinary tract infections (complicated and uncomplicated)
• Chronic bacterial prostatitis
• Skin and skin structure infections (complicated and uncomplicated)
• Inhalation anthrax (post-exposure prophylaxis)
• Plague (treatment and prophylaxis) [1, 2]

What is LEVAQUIN's Patent and Exclusivity Landscape?

The original composition of matter patent for levofloxacin has long expired, enabling generic competition. Key patent and exclusivity milestones relevant to LEVAQUIN include:

• Original Composition of Matter Patent: Granted in the 1980s, this patent provided the initial market exclusivity.
• Orphan Drug Exclusivity: Not applicable to LEVAQUIN as it was not developed for a rare disease.
• New Chemical Entity (NCE) Exclusivity: Levofloxacin, as a distinct entity from ofloxacin, may have received NCE exclusivity upon its initial approval.
• Pediatric Exclusivity: An extension of 6 months was granted for studies conducted in pediatric populations, extending exclusivity until the early 2000s.
• Method of Use Patents: Johnson & Johnson pursued patents covering specific uses, dosages, or formulations of levofloxacin. These patents faced numerous legal challenges and expirations.

The primary patent protection for the core molecule expired in the early 2000s. Subsequent patents related to specific formulations or methods of treatment also faced expiration or were invalidated through litigation. This opened the door for significant generic market entry.

How Has LEVAQUIN's Market Penetration Evolved?

LEVAQUIN achieved substantial market penetration following its introduction in 2000. Its broad spectrum of activity and favorable pharmacokinetic profile made it a preferred agent for numerous bacterial infections.

• Peak Sales: LEVAQUIN’s peak sales were in the mid-to-late 2000s, exceeding $1 billion annually. In 2010, it generated approximately $1.3 billion in revenue for Johnson & Johnson. [3]
• Market Share: At its peak, LEVAQUIN held a significant share within the fluoroquinolone market and the broader antibiotic market for its approved indications.
• Generic Entry Impact: Following patent expirations around 2008-2010, multiple generic versions of levofloxacin entered the market. This led to a rapid decline in LEVAQUIN's market share and average selling price.

Comparative Market Performance: LEVAQUIN vs. Other Fluoroquinolones (Peak Year Example)

Drug	Peak Annual Sales (Approx.)	Year of Peak	Primary Indication
LEVAQUIN	$1.3 billion	2010	Pneumonia, UTIs, Sinusitis, Skin Infections
Cipro (Ciprofloxacin)	$1.5 billion	Early 2000s	UTIs, Anthrax, Bacterial Gastroenteritis
Avelox (Moxifloxacin)	$800 million	Mid-2010s	Pneumonia, Sinusitis, Skin Infections

Note: Peak sales figures are approximate and can vary based on reporting sources and market fluctuations.

What Are the Key Market Drivers and Restraints for Levofloxacin?

Market Drivers:

• Efficacy Against Resistant Organisms: Levofloxacin demonstrates activity against a range of Gram-positive and Gram-negative bacteria, including some strains resistant to older antibiotics.
• Broad Spectrum of Activity: Its broad spectrum simplifies treatment regimens for complicated infections where the causative pathogen is not yet identified.
• Availability of Generic Versions: The presence of affordable generic levofloxacin ensures continued accessibility for healthcare providers and patients.
• Established Clinical Use: Decades of clinical experience and integration into treatment guidelines contribute to its continued use.

Market Restraints:

• Safety Concerns and Black Box Warnings: Fluoroquinolones, including levofloxacin, carry significant safety warnings regarding serious adverse events, such as tendonitis and tendon rupture, peripheral neuropathy, central nervous system effects (including CNS depression and toxicity), and exacerbation of myasthenia gravis. The U.S. Food and Drug Administration (FDA) has strengthened these warnings over time. [4, 5]
• Emergence of Resistance: Like all antibiotics, overuse and misuse of levofloxacin contribute to the development of antibiotic resistance, limiting its efficacy in certain settings.
• Stricter Prescribing Guidelines: Regulatory bodies and professional organizations recommend limiting fluoroquinolone use, particularly for uncomplicated infections, due to the risk of serious side effects and the availability of safer alternatives.
• Competition from Newer Antibiotics: Development of new antibiotic classes and agents with potentially improved safety profiles or activity against resistant pathogens presents competitive pressure.
• Declining Brand Value: Genericization significantly erodes the premium pricing and market dominance previously held by LEVAQUIN.

What is the Current and Projected Financial Trajectory of Levofloxacin?

The financial trajectory of levofloxacin has shifted from blockbuster brand sales to a mature generic market.

• Generic Market Dominance: The market is now dominated by generic levofloxacin. Brand-name LEVAQUIN sales have drastically diminished.
• Price Erosion: Generic competition has led to substantial price erosion, with levofloxacin tablets and solutions available at a fraction of the original brand price.
• Market Volume: While dollar sales have decreased significantly, the overall volume of levofloxacin prescribed and dispensed remains substantial due to its affordability and continued clinical utility for specific indications.
• Projected Revenue: Projections for levofloxacin as a global market focus on the aggregate sales of all levofloxacin generics. The total market value is expected to remain relatively stable or see modest growth, driven by volume in emerging markets and specific treatment needs, rather than significant price appreciation. The market size for levofloxacin generics is estimated to be in the hundreds of millions of U.S. dollars annually, a stark contrast to LEVAQUIN's peak brand revenue. [6]

Key Financial Indicators (Post-Patent Expiration)

Indicator	Description	Trend
Brand Sales (LEVAQUIN)	Revenue generated by Johnson & Johnson from the branded product.	Drastically declined post-patent expiration.
Generic Levofloxacin Sales	Aggregate revenue from all manufacturers producing generic levofloxacin.	Primary revenue driver for the molecule.
Average Selling Price (ASP)	The average price at which levofloxacin is sold, considering both branded and generic products.	Significantly decreased due to generic competition.
Market Volume (Units)	The total number of prescriptions or units dispensed for levofloxacin.	Remains substantial, supported by generic availability.
Market Share	LEVAQUIN's share of the fluoroquinolone market.	Minimal for branded LEVAQUIN, high for generic levofloxacin.

What are the Regulatory and Clinical Landscape Considerations?

Regulatory actions and evolving clinical practices profoundly impact levofloxacin's market position.

• FDA Safety Communications: The FDA has issued multiple safety alerts and strengthened black box warnings for fluoroquinolones due to serious adverse events. These include warnings about disabling and potentially permanent side effects involving tendons, muscles, joints, nerves, and the central nervous system. [4, 5]
• Restrictions on Use: In 2018, the FDA advised against using fluoroquinolones for patients with uncomplicated sinusitis, acute bacterial exacerbations of chronic bronchitis, and uncomplicated urinary tract infections when other treatment options are available. [5] This recommendation aims to reduce the risk of serious side effects.
• Antimicrobial Stewardship Programs: Healthcare institutions increasingly implement antimicrobial stewardship programs that promote the judicious use of antibiotics, including fluoroquinolones, favoring agents with better safety profiles or narrower spectra of activity when appropriate.
• International Regulations: Similar scrutiny and evolving guidance exist in other major markets, influencing prescribing patterns and market access.

Key Takeaways

• LEVAQUIN (levofloxacin) transitioned from a blockbuster branded antibiotic to a mature generic product following patent expirations in the early 2000s.
• Generic competition has led to significant price erosion, with aggregate global sales of levofloxacin generics now in the hundreds of millions of dollars annually.
• Significant safety concerns, including black box warnings for serious adverse events, have led to restricted prescribing guidelines by regulatory bodies and a trend towards using levofloxacin only when other treatment options are inadequate.
• The continued market presence of levofloxacin is driven by its efficacy against a broad range of pathogens and the availability of affordable generic formulations, but its future growth is constrained by safety considerations and the emergence of newer therapeutic alternatives.

Frequently Asked Questions

1. What is the current U.S. market status for branded LEVAQUIN versus generic levofloxacin? Branded LEVAQUIN has minimal market presence in the U.S. The market is overwhelmingly dominated by generic levofloxacin products.

2. What are the primary reasons for the decline in LEVAQUIN's brand value? The primary reasons are patent expiration, leading to intense generic competition, and the associated significant price erosion.

3. How do the FDA's safety warnings affect the current prescribing of levofloxacin? The FDA's warnings, particularly the black box warnings, advise against using fluoroquinolones like levofloxacin for uncomplicated infections when alternative treatments exist, thereby limiting its use to more severe or complicated conditions.

4. Are there any new patents being filed or considered for levofloxacin that could impact its market exclusivity? Given the age of the core compound, new composition of matter patents are highly unlikely. Any future patent filings would likely pertain to novel formulations, delivery systems, or specific combination therapies, which would require significant innovation to gain market exclusivity and would face a high bar for approval.

5. What is the projected outlook for the global levofloxacin market in the next five years? The global levofloxacin market, comprised of generics, is projected to remain relatively stable, with potential for modest growth driven by increased volume in developing markets and its continued use in specific indications. However, significant price increases are not anticipated due to established generic competition and ongoing safety scrutiny.

Citations

[1] Product Information: LEVAQUIN® (levofloxacin) Tablets. Ortho-McNeil Pharmaceutical, Inc. Revision Date: July 2010. (Archived Label Information) [2] FDA. (2017, July 19). Levofloxacin Tablets, Oral Solution. DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69870880-615f-4408-8f4f-a4124f6287e0 [3] Johnson & Johnson. (2011). 2010 Annual Report. [4] FDA. (2018, December 11). FDA strengthens warnings on fluoroquinolone antibiotics. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-strengthens-warnings-fluoroquinolone-antibiotics [5] FDA. (2018, December 6). FDA advises restricting fluoroquinolone antibiotic use for uncomplicated sinus and urinary tract infections. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-restricting-fluoroquinolone-antibiotic-use-uncomplicated-sinus-and-urinary-tract-infections [6] Market Research Reports (Various Sources, e.g., Grand View Research, Mordor Intelligence, Statista - aggregated data for global levofloxacin market size). Specific report dates and figures vary; general consensus on market size in the hundreds of millions USD range post-genericization.